{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:34:06Z","timestamp":1790116446708,"version":"4.0.1"},"reference-count":120,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Pers. Med.","JPM"],"abstract":"<jats:p>After many years of stagnation in the treatment of acute myeloid leukemia (AML), there is currently a rapid move towards personalized medicine. Improvements in molecular diagnostics, risk assessment tools, targeted therapies, overall patient fitness assessments, and quality-of-life assessments have significantly changed how patients are treated. Genetic and molecular analyses, risk and health assessments, and measurable residual disease (MRD) monitoring are now integral to the treatment plan for evaluating patient responses and recurrence. In this regard, lower-intensity treatments are provided to older or unfit individuals. On the other hand, younger patients are usually subjected to curative therapies such as intensive chemotherapy to induce remission. Depending on their fitness and disease risk, they can be considered for hematopoietic cell transplantation, which is done after close observation for MRD. In addition, newer therapeutic drugs and immunotherapy techniques are being applied for patient management. Tremendous strides have been made in improving the efficiency of treatment programs in the relatively new area of personalized AML therapy, with a focus on functionality.<\/jats:p>","DOI":"10.3390\/jpm16050266","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:19:29Z","timestamp":1778854769000},"page":"266","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evolving Management Approaches Toward Personalized Therapy in Acute Myeloid Leukemia: A Narrative Review"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-6518","authenticated-orcid":false,"given":"Pasquale","family":"Niscola","sequence":"first","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gianfelici","sequence":"additional","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giovannini","sequence":"additional","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Mazzone","sequence":"additional","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Del Principe","sequence":"additional","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"},{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Jeurkar, C., King, L., Baek, D., Wilde, L., Keiffer, G., and Kasner, M. (2026). Management of Acute Myeloid Leukemia: A Review. Cancers, 18.","DOI":"10.3390\/cancers18040659"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.21037\/atm-23-1824","article-title":"Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression","volume":"12","author":"Urs","year":"2024","journal-title":"Ann. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bao, J., Freund, O., Sund, L., and Du, W. (2026). Inside the Battle Against Acute Myeloid Leukemia: Biology, Breakthroughs, and Hope. Cells, 15.","DOI":"10.3390\/cells15040338"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.21037\/apm-25-32","article-title":"Palliative care interventions and their early integration in the management of older adults with acute myeloid leukemia: A narrative review","volume":"14","author":"Niscola","year":"2025","journal-title":"Ann. Palliat. Med."},{"key":"ref_8","first-page":"1","article-title":"Transforming Acute Myeloid Leukemia Care Through Precision Medicine: Integrating Genomic Profiling, Measurable Residual Disease, and Targeted Therapies","volume":"30","author":"Benkhadra","year":"2026","journal-title":"Oncology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2024013744","article-title":"Fitness assessment in acute myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"9","author":"Venditti","year":"2025","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yadav, S.K., Joshi, U., Hussein, G., Warsame, M., Liu, B., Shrestha, A., Krastev, P., Korsapati, H.R., and Singh, A. (2025). Evolving Paradigms in Acute Myeloid Leukemia: Personalized Approaches to Therapy Across Age and Risk Groups. Cancers, 17.","DOI":"10.3390\/cancers17172824"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2024026186","article-title":"Acute promyelocytic leukemia: Long-term outcomes from the HARMONY project","volume":"145","author":"Voso","year":"2025","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/beha.2000.0115","article-title":"Molecular genetics of acute myeloid leukaemia","volume":"14","author":"Dash","year":"2001","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bhowmik, S., Bose, A., and Sengupta, A. (2025). Innate immune-inflammatory signaling milieu in myeloid leukemia and aging-associated clonal hematopoiesis pathologies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1660709"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/ijc.70024","article-title":"Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta-analysis","volume":"157","author":"Lin","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105090","DOI":"10.1016\/j.critrevonc.2025.105090","article-title":"The role of the bone marrow microenvironment in leukemic stem cell resistance: Pathways of persistence and selection","volume":"218","author":"Barachini","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12015-025-11011-6","article-title":"Mesenchymal Stromal Cells: Bridging the Gaps in Hematologic Disease Therapy","volume":"22","author":"Zhao","year":"2026","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Skelding, K.A., Barry, D.L., and Lincz, L.F. (2025). Modeling the Bone Marrow Microenvironment to Better Understand the Pathogenesis, Progression, and Treatment of Hematological Cancers. Cancers, 17.","DOI":"10.3390\/cancers17152571"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"117999","DOI":"10.1016\/j.biopha.2025.117999","article-title":"The hypoxia signaling pathway in the development of acute myeloid leukemia","volume":"186","author":"Yang","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e35721","DOI":"10.1016\/j.heliyon.2024.e35721","article-title":"Glycolysis and chemoresistance in acute myeloid leukemia","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/bloodadvances.2024013304","article-title":"Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia","volume":"9","author":"Ruhnke","year":"2025","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"Pratz","year":"2024","journal-title":"Blood"},{"key":"ref_28","first-page":"1095","article-title":"Prognostic value of European LeukemiaNet 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia","volume":"109","author":"Park","year":"2024","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e70375","DOI":"10.1002\/cncr.70375","article-title":"Beyond age: Frailty-guided care in hematologic malignancies","volume":"132","author":"Friend","year":"2026","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2212536","DOI":"10.1080\/16078454.2023.2212536","article-title":"Treatment of acute myeloid leukaemia in older patients\u2014Scope of intensive therapy?\u2014A retrospective analysis","volume":"28","author":"Mayer","year":"2023","journal-title":"Hematology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101224","DOI":"10.1016\/j.blre.2024.101224","article-title":"Breaking down frailty: Assessing vulnerability in acute myeloid leukemia","volume":"68","author":"Williams","year":"2024","journal-title":"Blood Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/bloodadvances.2023011804","article-title":"Trajectories of physical well-being among adults with acute myeloid leukemia","volume":"8","author":"Sohn","year":"2024","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML","volume":"139","author":"Min","year":"2022","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102254","DOI":"10.1016\/j.jgo.2025.102254","article-title":"Geriatric assessment in older adults with acute myeloid leukemia: A Young International Society of Geriatric Oncology narrative review","volume":"16","author":"Ciccone","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: A project of SIE, SIES, and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.20.01392","article-title":"Accuracy of SIE\/SIES\/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults with AML or Other High-Grade Myeloid Neoplasm","volume":"38","author":"Palmieri","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/bloodadvances.2025017089","article-title":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351","volume":"10","author":"Palmieri","year":"2025","journal-title":"Blood Adv."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/bjh.19022","article-title":"Validation of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukemia patients treated with hypomethylating agents and venetoclax","volume":"203","author":"Apolito","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1080\/10428194.2023.2186731","article-title":"Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed\/refractory AML","volume":"64","author":"Ritchie","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/17474086.2025.2521397","article-title":"Determining treatment pathways for older patients with acute myeloid leukemia: Patient and clinician perspectives","volume":"18","author":"Oliva","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101793","DOI":"10.1016\/j.jgo.2024.101793","article-title":"Exploring the role of the oncologist in promoting shared decision-making during treatment planning for older adults with acute myeloid leukemia","volume":"15","author":"LoCastro","year":"2024","journal-title":"J. Geriatr. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.21234","article-title":"Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome","volume":"104","author":"Meyers","year":"2005","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/ajh.27694","article-title":"A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults with AML","volume":"100","author":"Bhatt","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101582","DOI":"10.1016\/j.jgo.2023.101582","article-title":"Prognostic significance of the Geriatric 8 score alone and included with genetic risk group in older adults with acute myeloid leukemia","volume":"14","author":"Fujita","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11912-025-01671-5","article-title":"Evaluation and Prognostic Impact of Nutrition in Patients with Acute Leukemia: A Narrative Review","volume":"27","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"102335","DOI":"10.1016\/j.jgo.2025.102335","article-title":"Objectively measured physical function predicts mortality in older adults with acute myeloid leukemia treated by lower-intensity therapy: A prospective cohort study","volume":"16","author":"Kwag","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1200\/OP-25-00601","article-title":"Objective Performance Status: Enhancing Cancer Patient Fitness Assessment with Wearable Technology","volume":"22","author":"McCollom","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood.2023023313","article-title":"Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia","volume":"144","author":"Le","year":"2024","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1080\/10428194.2025.2547993","article-title":"Flow cytometric and molecular MRD in AML: Current methods, clinical applications and challenges","volume":"66","author":"Haaksma","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/bjh.70038","article-title":"Measurable residual disease-guided therapy in acute myeloid leukemia: Practical insights","volume":"207","author":"Nachmias","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","article-title":"Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms","volume":"15","author":"Gangat","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2025017934","article-title":"American Society of Hematology 2025 guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults","volume":"10","author":"Sekeres","year":"2025","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjh.19519","article-title":"Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease","volume":"205","author":"Jen","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_55","first-page":"1897","article-title":"The new era of AML therapy: Current standards and emerging targets","volume":"10","author":"Hosono","year":"2026","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"102604","DOI":"10.1016\/j.coph.2025.102604","article-title":"Advancements in targeted therapies for acute myeloid leukemia","volume":"87","author":"Connor","year":"2025","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_57","first-page":"e95338","article-title":"Current Therapeutic Strategies for FLT3-Mutated Acute Myeloid Leukemia: A Narrative Review","volume":"17","author":"Swanson","year":"2025","journal-title":"Cureus"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41375-025-02700-9","article-title":"Gemtuzumab ozogamicin in first-line treatment of CBF-AML: Insights from a retrospective multi-center analysis","volume":"39","author":"Ronnacker","year":"2025","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Konstantinidis, I., Tsokkou, S., Keramas, A., Gavriilaki, E., Delis, G., and Papamitsou, T. (2025). CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311628"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/bloodadvances.2025019378","article-title":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial","volume":"10","author":"Shimony","year":"2026","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: Post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukemia (ASCERTAIN): A registrational, randomized, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"McCloskey","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(24)00033-4","article-title":"Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: A phase 2 study","volume":"11","author":"Bazinet","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.3324\/haematol.2021.279174","article-title":"Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase 3, placebo-controlled QUAZAR AML-001 trial","volume":"106","author":"Roboz","year":"2021","journal-title":"Haematologica"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: The Alliance CALGB 10603\/RATIFY trial","volume":"35","author":"Larson","year":"2021","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"107564","DOI":"10.1016\/j.leukres.2024.107564","article-title":"Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed\/refractory FLT3mut acute myeloid leukemia","volume":"145","author":"Fu","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition with Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_73","first-page":"1126","article-title":"Outcomes with intensive treatment for acute myeloid leukemia: An analysis of two decades of data from the HARMONY Alliance","volume":"110","author":"Sobas","year":"2025","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"100829","DOI":"10.1016\/j.blre.2021.100829","article-title":"AML and the art of remission maintenance","volume":"49","author":"Roboz","year":"2021","journal-title":"Blood Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO-25-01841","article-title":"Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study","volume":"44","author":"Montesinos","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1200\/JCO.22.02721","article-title":"Gilteritinib in Combination with Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients with Newly Diagnosed AML","volume":"41","author":"Pratz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e03194","DOI":"10.1002\/cbdv.202503194","article-title":"Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia","volume":"23","author":"Dai","year":"2026","journal-title":"Chem. Biodivers."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/s41375-025-02733-0","article-title":"Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax","volume":"39","author":"Croden","year":"2025","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-025-01378-6","article-title":"Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia","volume":"27","author":"Peters","year":"2026","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1080\/14656566.2025.2582022","article-title":"Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia","volume":"26","author":"Niscola","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e3260","DOI":"10.1002\/hon.3260","article-title":"Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis","volume":"42","author":"Wang","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bjh.70253","article-title":"Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7\u2009+\u20093 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia","volume":"208","author":"Lee","year":"2026","journal-title":"Br. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"20406207251319603","DOI":"10.1177\/20406207251319603","article-title":"Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Zhang","year":"2025","journal-title":"Ther. Adv. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","article-title":"Long-term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2025","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e70214","DOI":"10.1002\/hem3.70214","article-title":"A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia","volume":"9","author":"Jen","year":"2025","journal-title":"Hemasphere"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14796694.2025.2469487","article-title":"Risk-stratified treatment of sonrotoclax with chemotherapy in newly diagnosed acute myeloid leukemia: A study protocol","volume":"21","author":"Zhang","year":"2025","journal-title":"Future Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1159\/000547487","article-title":"Acute Myeloid Leukemia with BCR::ABL1+ Fusion: A Report of Two Cases and Review of Literature","volume":"18","author":"Dabrowski","year":"2025","journal-title":"Case Rep. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14737140.2023.2238897","article-title":"Oral therapy for myelodysplastic syndromes\/neoplasms and acute myeloid leukemia: A revolution in progress","volume":"23","author":"Venugopal","year":"2023","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2025.08.016","article-title":"Comparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60-75 Years: A Propensity Score-Adjusted Cohort Study","volume":"26","author":"Albliwi","year":"2026","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2025-6","article-title":"Results from paradigm\u2014A phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"146","author":"Fathi","year":"2025","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"108179","DOI":"10.1016\/j.leukres.2026.108179","article-title":"CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis","volume":"162","author":"Miyashita","year":"2026","journal-title":"Leuk. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO-25-00640","article-title":"Outcomes of Frontline Triplet Regimens with a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients with Isocitrate Dehydrogenase-Mutated AML","volume":"43","author":"DiNardo","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3324\/haematol.2025.288553","article-title":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor","volume":"111","author":"Short","year":"2026","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/hematology.2025000745","article-title":"Peri-transplant conundrums: Optimizing maintenance therapy using MRD-directed approaches","volume":"2025","author":"Raychaudhuri","year":"2025","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2026.2710392","article-title":"New horizons for hope of cure in acute myeloid leukemia through immunotherapy: A narrative review","volume":"10","author":"Niscola","year":"2026","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/bjh.70272","article-title":"Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial","volume":"208","author":"Voso","year":"2026","journal-title":"Br. J. Haematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/hematology.2025000755","article-title":"The promise of menin inhibitors: From approval to triplet regimens","volume":"2025","author":"Thakur","year":"2025","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.27584","article-title":"Treatment of Relapsed\/Refractory AML-Novel Treatment Options Including Immunotherapy","volume":"100","author":"Moore","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/17474086.2025.2547866","article-title":"Therapeutic options for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation","volume":"18","author":"Yolcu","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2025-652","article-title":"\u03b39\u03b42 T-cell (\u03b39\u03b42TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1\/2 study eviction","volume":"146","author":"Garciaz","year":"2025","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Atilla, E., and Benabdellah, K. (2023). The Black Hole: CAR T Cell Therapy in AML. Cancers, 15.","DOI":"10.20944\/preprints202304.0482.v1"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40364-023-00501-9","article-title":"Biomarkers as targets for CAR-T\/NK cell therapy in AML","volume":"11","author":"Shao","year":"2023","journal-title":"Biomark. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"117024","DOI":"10.1016\/j.biopha.2024.117024","article-title":"CAR-NK cell therapy in AML: Current treatment, challenges, and advantage","volume":"177","author":"Bahramloo","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1186\/s12967-025-07151-5","article-title":"CAR-T and CAR-NK cell therapies in AML: Breaking barriers and charting the future","volume":"23","author":"Wu","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e432650","DOI":"10.1200\/EDBK_432650","article-title":"TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates","volume":"44","author":"Santini","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Kamihara, Y., Kikuchi, S., Ishikawa, N., Shinomiya, N., Kunimoto, K., Horaguchi, R., Fujihira, T., Nabe, Y., Minemura, T., and Ono, K. (2026). Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia. PLoS ONE, 21.","DOI":"10.1371\/journal.pone.0341461"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Pessoa, F.M.C.P., Farias, I.M., Nogueira, B.M.D., Machado, C.B., Barreto, I.V., Machado, A.K.D.C., de Morais, G.P., da Cunha, L.S., de Sousa Oliveira, D., and Th\u00e9, A.P. (2025). Pharmacogenomics Applied to Acute Leukemias: Identifying Clinically Relevant Genetic Variants. Biomedicines, 13.","DOI":"10.3390\/biomedicines13112581"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/FTD.0000000000001151","article-title":"Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication","volume":"46","author":"Philippe","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.16708","article-title":"Supportive care in the management of patients with acute myeloid leukaemia: Where are the research needs?","volume":"190","author":"Loke","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Mezzanotte, V., Paterno, G., Cerroni, I., De Marchi, L., Taka, K., Buzzatti, E., Mallegni, F., Meddi, E., Moretti, F., and Buccisano, F. (2025). Use of Primary Prophylaxis with G-CSF in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy Does Not Affect Quality of Response. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041254"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/07357907.2024.2352454","article-title":"The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis","volume":"42","author":"Bordbar","year":"2024","journal-title":"Cancer Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"100217","DOI":"10.1016\/j.bneo.2026.100217","article-title":"Artificial intelligence-based prognostic models in acute myeloid leukemia: Systematic review and meta-analysis","volume":"3","author":"Zhang","year":"2026","journal-title":"Blood Neoplasia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12185-025-04097-8","article-title":"Azacitidine monotherapy versus combination regimens as post-HSCT maintenance therapy in high-risk myeloid malignancies: A retrospective cohort study","volume":"123","author":"Shen","year":"2026","journal-title":"Int. J. Hematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ajh.70247","article-title":"The Care and Cure of the Leukemias in 2026","volume":"101","author":"Kantarjian","year":"2026","journal-title":"Am. J. Hematol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/5\/266\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:31:21Z","timestamp":1785400281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/5\/266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":120,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jpm16050266"],"URL":"https:\/\/doi.org\/10.3390\/jpm16050266","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}